1.Ray MA, Faris NR, Smeltzer MP, Fehnel C, Houston-Harris C, Levy P, Wiggins L, Sachdev V, Robbins T, Spencer D et al: Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer. ANN THORAC SURG 2018, 106(1):228–234.
2.Wu M, Pan X, Xu Y, Wu S, Wu X, Chen B: Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics. ONCOL LETT 2018, 16(1):1087–1094.
3.Bracht J, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. CURR ONCOL REP 2018, 20(9):70.
4.Wang Z, Cheng Y, An T, Gao H, Wang K, Zhou Q, Hu Y, Song Y, Ding C, Peng F et al: Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med 2018, 6(9):681–690.
5.Minnix JA, Karam-Hage M, Blalock JA, Cinciripini PM: The importance of incorporating smoking cessation into lung cancer screening. Transl Lung Cancer Res 2018, 7(3):272–280.
6.Cao Q, Rui G, Liang Y: Study on PM2.5 pollution and the mortality due to lung cancer in China based on geographic weighted regression model. BMC PUBLIC HEALTH 2018, 18(1):925.
7.Jung J, Feinstein SG, Palma LL, Macleod JS, Arrandale VH, McLeod CB, Peter A, Demers PA: Examining lung cancer risks across different industries and occupations in Ontario, Canada: the establishment of the Occupational Disease Surveillance System. OCCUP ENVIRON MED 2018, 75(8):545–552.
8.Zhao S, Chen F, Wang D, Wang H, Han W, Zhang Y: Effect of preoperative smoking cessation on postoperative pain outcomes in elderly patients with high nicotine dependence. Medicine (Baltimore) 2019, 98(3):e14209.
9.Ozga JE, Anderson KG: Reduction in delay discounting due to nicotine and its attenuation by cholinergic antagonists in Lewis and Fischer 344 rats. Psychopharmacology (Berl) 2018, 235(1):155–168.
10.Xun WW, Brennan P, Tjonneland A, Vogel U, Overvad K, Kaaks R, Canzian F, Boeing H, Trichopoulou A, Oustoglou E et al: Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC). MUTAGENESIS 2011, 26(5):657–666.
11.Wen L, Jiang K, Yuan W, Cui W, Li MD: Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism. MOL NEUROBIOL 2016, 53(1):472–484.
12.Ellerbeck EF, Nollen N, Hutcheson TD, Phadnis M, Fitzgerald SA, Vacek J, Sharpe MR, Salzman GA, Richter KP: Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. JAMA Netw Open 2018, 1(5):e181843.
13.Huang CY, Xun XJ, Wang AJ, Gao Y, Ma JY, Chen YT, Jin TB, Hou P, Gu SZ: CHRNA5 polymorphisms and risk of lung cancer in Chinese Han smokers. AM J CANCER RES 2015, 5(10):3241–3248.
14.Anantharaman D, Chabrier A, Gaborieau V, Franceschi S, Herrero R, Rajkumar T, Samant T, Mahimkar MB, Brennan P, McKay JD: Genetic variants in nicotine addiction and alcohol metabolism genes, oral cancer risk and the propensity to smoke and drink alcohol: a replication study in India. PLOS ONE 2014, 9(2):e88240.
15.Zhao Z, Zhou Y, Li Y, Jiang C, Zhao D, Zhao Z, Liu Z, Ran P: An efficient method to genotype the polymorphisms of cholinergic nicotinic receptor subunit genes and their associations with COPD onset risk. EXP LUNG RES 2016, 42(5):267–274.
16.Tekpli X, Landvik NE, Skaug V, Gulsvik A, Haugen A, Zienolddiny S: Functional effect of polymorphisms in 15q25 locus on CHRNA5 mRNA, bulky DNA adducts and TP53 mutations. INT J CANCER 2013, 132(8):1811–1820.
17.Berrettini WH, Doyle GA: The CHRNA5-A3-B4 gene cluster in nicotine addiction. Mol Psychiatry 2012, 17(9):856–866.
18.Shen B, Zhu Q, Zheng MQ, Chen J, Shi MQ, Feng JF: CHRNA5 polymorphism and susceptibility to lung cancer in a Chinese population. BRAZ J MED BIOL RES 2013, 46(1):79–84.
19.Yoo SS, Kang HG, Choi JE, Do SK, Lee WK, Choi SH, Lee SY, Lee SY, Lee J, Cha SI et al: Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer. Cancer Genet 2017, 212–213:8–12.
20.Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED, Burdette L, Cai Q, Caporaso N, Chung CC et al: Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. LUNG CANCER 2016, 98:33–42.
21.Hallden S, Sjogren M, Hedblad B, Engstrom G, Hamrefors V, Manjer J, Melander O: Gene variance in the nicotinic receptor cluster (CHRNA5-CHRNA3-CHRNB4) predicts death from cardiopulmonary disease and cancer in smokers. J INTERN MED 2016, 279(4):388–398.
22.Wang Y, Wu H, Liu Q, Wang C, Fu L, Wang H, Zhu W, Fu W, Lv Y, Wang S et al: Association of CHRNA5-A3-B4 variation with esophageal squamous cell carcinoma risk and smoking behaviors in a Chinese population. PLOS ONE 2013, 8(7):e67664.
23.Cron KR, Zhu K, Kushwaha DS, Hsieh G, Merzon D, Rameseder J, Chen CC, D’Andrea AD, Kozono D: Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. PLOS ONE 2013, 8(9):e73710.
24.Ling YH, Liebes L, Zou Y, Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells, vol. 278; 2003.
25.Song H, Xiong H, Che J, Xi QS, Huang L, Xiong HH, Zhang P: Gel-based chemical cross-linking analysis of 20S proteasome subunit-subunit interactions in breast cancer. J Huazhong Univ Sci Technolog Med Sci 2016, 36(4):564–570.
26.Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F: The RNA-binding protein Musashi–1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. STEM CELLS 2014, 32(1):135–144.
27.Okumura T, Ikeda K, Ujihira T, Okamoto K, Horie-Inoue K, Takeda S, Inoue S: Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation. J BIOCHEM 2018, 163(1):19–29.
28.Taromi S, Lewens F, Arsenic R, Sedding D, Sanger J, Kunze A, Mobs M, Benecke J, Freitag H, Christen F et al: Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. Oncotarget 2017, 8(57):97061–97078.
29.Chen YJ, Wu H, Shen XZ: The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. CANCER LETT 2016, 379(2):245–252.
30.Wu T, Chen W, Zhong Y, Hou X, Fang S, Liu CY, Wang G, Yu T, Huang YY, Ouyang X et al: Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor. MOL CANCER THER 2017, 16(4):717–728.
31.Wang T, Chen T, Thakur A, Liang Y, Gao L, Zhang S, Tian Y, Jin T, Liu JJ, Chen M: Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population. Clinical and Translational Oncology 2015, 17(7):564–569.